Biogen Inc header image

Biogen Inc

BIIB

Equity

ISIN US09062X1037 / Valor 1720684

NASDAQ (2024-09-18)
USD 197.59-0.31%

Biogen Inc
UMushroom community rating:

star star star star star
4.40 5 votes No rating yet
NegativeNeutralPositive

About company

Biogen Inc is a prominent biotechnology company that focuses on developing therapies for a range of complex and debilitating diseases. Established in 1978, the company has made significant advancements in the field, particularly in neurology, neuropsychiatry, specialized immunology, and rare diseases. Biogen is known for its innovative treatments for conditions such as multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease. The company is dedicated to serving humanity through scientific research and is committed to creating a healthier, more sustainable, and equitable world.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-22.0%1Y
-34.2%3Y
-16.0%5Y

Performance

26.3%1Y
33.7%3Y
45.2%5Y

Volatility

Market cap

28872 M

Market cap (USD)

Daily traded volume (Shares)

346,232

Daily traded volume (Shares)

1 day high/low

202.72 / 197.12

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.40

5 votes
Performance:
starstarstarstarstar
4.20
Innovation:
starstarstarstarstar
4.80
Society:
starstarstarstarstar
4.20
Nature:
starstarstarstarstar
4.00
Tonia Zimmermann
Switzerland, 13 Jun 2023
star star star star star
Not just leading in supporting Alzheimer patience, but also pioneering in digital health.
Igor Jovicic
Switzerland, 13 Jun 2023
star star star star star
A company that seems to be making an impact in the biotech sector!
Luba Schoenig
Switzerland, 13 Jun 2023
star star star star star
FDA Advisory Committee recommended the Food and Drug Administration to approve Leqembi, an Alzheimer's drug from Biogen and its Japanese partner Eisai.

EQUITIES OF THE SAME SECTOR

Kaken Seiyaku KK
Kaken Seiyaku KK Kaken Seiyaku KK Valor: 762167
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.20%JPY 3,915.00
Illumina Inc
Illumina Inc Illumina Inc Valor: 1111080
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.58%USD 130.97
GE Healthcare Technologies Inc
GE Healthcare Technologies Inc GE Healthcare Technologies Inc Valor: 123735674
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.00%USD 88.53
Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc Alnylam Pharmaceuticals Inc Valor: 1806798
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.48%USD 273.15
Henry Schein Inc
Henry Schein Inc Henry Schein Inc Valor: 83527
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.71%USD 72.46
BeiGene Ltd
BeiGene Ltd BeiGene Ltd Valor: 30165310
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.12%USD 197.28
Laboratorios Farmaceuticos Rovi, SA
Laboratorios Farmaceuticos Rovi, SA Laboratorios Farmaceuticos Rovi, SA Valor: 3591807
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.07%EUR 73.95
Almirall SA
Almirall SA Almirall SA Valor: 3180354
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.12%EUR 8.51
Pharma Mar SA
Pharma Mar SA Pharma Mar SA Valor: 56130572
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
5.65%EUR 45.26
KK Kose
KK Kose KK Kose Valor: 1017515
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.88%JPY 7,930.00